Campbell Duncan J, Neal Bruce C, Chalmers John P, Colman Samuel A, Jenkins Alicia J, Kemp Bruce E, Patel Anushka, Macmahon Stephen W, Woodward Mark
St. Vincent's Institute of Medical Research, Fitzroy, Victoria, Australia.
Eur J Cardiovasc Prev Rehabil. 2007 Jun;14(3):413-8. doi: 10.1097/HJR.0b013e328010f275.
Only limited data are available for risk factors for intracerebral haemorrhage (ICH) in subjects with established cerebrovascular disease.
We performed a nested case-control study of participants of the Perindopril Protection Against Recurrent Stroke Study (PROGRESS). This was a randomized, placebo-controlled trial that established the beneficial effects of blood pressure lowering in 6105 patients with cerebrovascular disease.
Each of 41 subjects who experienced ICH during a mean follow-up of 3.9 years was matched to 1-3 control subjects. Lipoprotein particles and other plasma markers were measured in baseline blood samples from PROGRESS participants.
In comparison with control subjects, ICH cases had increased mean low-density lipoprotein (LDL) diameter (P=0.04) and increased large LDL particle concentration (P=0.03). The odds ratio (adjusted for regression dilution bias) for ICH risk with 10 mmHg increase in systolic blood pressure (SBP) was 1.45 (95% confidence interval: 1.01-2.09, P=0.05), with a 1 nm increase in mean LDL diameter it was 2.15 (95% confidence interval: 0.97-4.77, P=0.06), and with 100 nmol/l increase in large LDL particle concentration it was 1.18 (95% confidence interval: 0.98-1.43, P=0.08). Plasma levels of C-reactive protein (CRP), soluble vascular cell adhesion molecule 1 (sVCAM-1), homocysteine, amino-terminal-pro-B-type natriuretic peptide (NT-proBNP), and renin were not associated with ICH risk.
SBP predicted ICH risk in subjects with cerebrovascular disease, whereas CRP, sVCAM-1, homocysteine, NT-proBNP, and renin did not predict ICH risk. The trends for prediction of ICH risk by mean LDL particle diameter and large LDL particle concentration are hypothesis generating and require confirmation in larger studies.
关于已患脑血管疾病患者发生脑出血(ICH)的危险因素,仅有有限的数据。
我们对培哚普利预防复发性卒中研究(PROGRESS)的参与者进行了一项巢式病例对照研究。这是一项随机、安慰剂对照试验,证实了6105例脑血管疾病患者降压治疗的有益效果。
在平均3.9年的随访期间发生ICH的41名受试者,每名与1 - 3名对照受试者匹配。对PROGRESS参与者的基线血样进行脂蛋白颗粒和其他血浆标志物检测。
与对照受试者相比,ICH病例的平均低密度脂蛋白(LDL)直径增加(P = 0.04),大LDL颗粒浓度增加(P = 0.03)。收缩压(SBP)每升高10 mmHg,ICH风险的比值比(校正回归稀释偏倚后)为1.45(95%置信区间:1.01 - 2.09,P = 0.05);平均LDL直径每增加1 nm,为2.15(95%置信区间:0.97 - 4.77,P = 0.06);大LDL颗粒浓度每增加100 nmol/l,为1.18(95%置信区间:0.98 - 1.43,P = 0.08)。血浆C反应蛋白(CRP)、可溶性血管细胞黏附分子1(sVCAM - 1)、同型半胱氨酸、氨基末端前B型利钠肽(NT - proBNP)和肾素水平与ICH风险无关。
SBP可预测脑血管疾病患者的ICH风险,而CRP、sVCAM - 1、同型半胱氨酸、NT - proBNP和肾素不能预测ICH风险。平均LDL颗粒直径和大LDL颗粒浓度对ICH风险预测的趋势只是假设性的,需要在更大规模的研究中得到证实。